Reviva Pharmaceuticals presenting brilaroxazine Phase 3 data in schizophrenia at 2025 SIRS Congress

From GlobeNewswire: 2025-03-30 11:30:00

Reviva Pharmaceuticals Holdings, Inc. announced topline data from the Phase 3 RECOVER study on brilaroxazine in schizophrenia will be presented at the 2025 Congress of the Schizophrenia International Research Society. The presentation, titled “Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety,” will be on March 30th from 10:30 AM – 12:00 PM ET CST by Dr. Laxminarayan Bhat. Reviva focuses on developing therapies for CNS, inflammatory, and cardiometabolic diseases, with two drug candidates in its pipeline, brilaroxazine (RP5063) and RP1208. Patents have been granted for both in multiple countries.

For more information, visit the SIRS 2025 website. Corporate Contact: Reviva Pharmaceuticals Holdings, Inc., Investor Relations Contact: LifeSci Advisors, LLC.



Read more at GlobeNewswire: Reviva to Present Brilaroxazine Topline Data for Long-Term